BioNTech SE (BNTX) EBITDA (2018 - 2026)

BioNTech SE has reported EBITDA for 8 years, with the latest figure at -$375.8 million in Q4 2025.

• Quarterly EBITDA fell 336.63% year-over-year to -$375.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.6 billion (down 9.74% YoY) and the FY2025 annual result came in at -$1.6 billion, down 13.02% from the prior year.
• EBITDA declined to -$375.8 million in Q4 2025 per BNTX's latest filing, from -$54.8 million in the prior quarter.
• Over five years, EBITDA peaked at $6.1 billion in Q1 2022 and troughed at -$1.0 billion in Q2 2024.
• A 5-year average of $1.4 billion and a median of $119.2 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2025: EBITDA jumped 62488226.12% in 2022, then tumbled 575.48% in 2025.
• Over 5 years, EBITDA stood at $5376.3 in 2021, then surged by 62488226.12% to $3.4 billion in 2022, then tumbled by 83.15% to $566.2 million in 2023, then slumped by 71.95% to $158.8 million in 2024, then tumbled by 336.63% to -$375.8 million in 2025.
• According to Business Quant data, EBITDA over the past three periods registered -$375.8 million, -$54.8 million, and -$567.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.